ClinicalTrials.gg
RecruitingNCT07635342Updated Jun 9, 2026

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

A Phase 2 interventional study of Pyrotinib Maleate and Trastuzumab (H, 8mg/kg in HER2-positive Breast Cancer, sponsored by Hebei Medical University Fourth Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Hebei Medical University Fourth Hospital · Phase 2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Apr 2024, registered Jun 2026).
  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Planned enrollment
82nd of 366
182 · median 61
Started
2024
with 11 others
Phase 2
239 of 374
44 open now
Primary completion
2026-12
later than 38 of 85 live
Registered
372nd of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 82nd largest by planned enrollment of the 366 interventional ones that give a count, is one of 12 that started in 2024, is one of 239 in phase 2, reaches primary completion later than 38 of the 85 other live ones, and was the 372nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a single-arm, multicenter clinical study designed to evaluate the efficacy and safety of pyrotinib and trastuzumab combined with pegylated liposomal doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel for injection albumin bound as neoadjuvant therapy in patients with early HER2-positive breast cancer.

Eligible patients will receive 8 cycles of neoadjuvant treatment. Pyrotinib will be administered orally once daily, and trastuzumab will be administered intravenously every 3 weeks. During the first 4 cycles, patients will receive pegylated liposomal doxorubicin hydrochloride and cyclophosphamide. During the subsequent 4 cycles, patients will receive paclitaxel for injection albumin bound. The primary outcome is total pathological complete response rate. Secondary outcomes include breast pathological complete response rate, lymph node pathological complete response rate, objective response rate, event-free survival, distant disease-free survival, overall survival, and safety.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • Neoadjuvant Therapy
  • Pyrotinib
  • Trastuzumab
  • Pathological Complete Response
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 65 years.
  • Patients with previously untreated invasive breast cancer confirmed by pathological examination.
  • -positive breast cancer, defined as immunohistochemistry (IHC) 3+ or IHC 2+ with HER2 gene amplification confirmed by in situ hybridization (ISH), regardless of hormone receptor status.
  • Clinical stage T2N0-3M0 or any T/N1-N3M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
  • At least one according to version 1.1.
  • (ECOG) performance status of 0 or 1.
  • Adequate organ function, meeting all of the following criteria:
  • ≥100 g/L.
  • ≥1.5 × 10\^9/L.
  • count ≥100 × 10\^9/L.
  • Total ≤1 × (ULN).
  • and aspartate aminotransferase ≤1.5 × ULN.
  • Alkaline phosphatase ≤2.5 × ULN.
  • Blood urea nitrogen and serum creatinine ≤1.5 × ULN.
  • ≥55% by echocardiography.
  • Women of must have a negative serum pregnancy test within 7 days before enrollment and agree to use appropriate during the study and for 8 weeks after the last dose of study treatment.
  • Patients must voluntarily participate in the study, sign the form, have good compliance, and be willing to cooperate with follow-up.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of any anti-tumor therapy, including chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy.
  • Concurrent receipt of any other anti-tumor therapy.
  • Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer.
  • Stage IV breast cancer.
  • Breast cancer not confirmed by pathological examination.
  • History of other within 5 years, except cured carcinoma in situ of the cervix.
  • Severe dysfunction of major organs, including the heart, liver, or kidney.
  • Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors that may affect drug administration or absorption.
  • Participation in another drug clinical trial within 4 weeks before enrollment.
  • Known history of allergy to any component of the study treatment.
  • History of immunodeficiency, including positive test, virus infection, active virus infection, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
  • History of any cardiac disease, including arrhythmia requiring medication, myocardial infarction, heart failure, or any other cardiac disease judged by the investigator to make the patient unsuitable for this study.
  • Pregnant or breastfeeding women, women of with a positive baseline pregnancy test, or women of childbearing potential unwilling to use effective throughout the study.
  • Serious concomitant diseases that, in the investigator's judgment, may compromise patient safety or affect completion of the study, including but not limited to uncontrolled severe hypertension, severe diabetes mellitus, or active infection.
  • Clear history of neurological or psychiatric disorders, including epilepsy or dementia.
  • Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Pyrotinib Plus Trastuzumab and Neoadjuvant Chemotherapy

    Participants will receive 8 cycles of neoadjuvant treatment. Pyrotinib maleate will be administered orally at 400 mg once daily from Day 1 of Cycle 1. Trastuzumab will be administered intravenously at a loading dose of 8 mg/kg in Cycle 1, followed by 6 mg/kg on Day 1 of each 3-week cycle. During the first 4 cycles, participants will receive pegylated liposomal doxorubicin hydrochloride 35 mg/m² and cyclophosphamide 600 mg/m² intravenously on Day 1 of each 3-week cycle. During the subsequent 4 cycles, participants will receive paclitaxel for injection albumin bound 230-260 mg/m² intravenously on Day 1 of each 3-week cycle.

    Drug: Pyrotinib Maleate · Drug: Trastuzumab (H, 8mg/kg · Drug: pegylated liposomal doxorubicin hydrochloride · Drug: Cyclophosphamide · Drug: Paclitaxel for Injection Albumin Bound

Interventions

  • DrugShr-1258 dimaleateStudies of Shr-1258 dimaleateShr-1258 dimaleate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pyrotinib maleate will be administered orally at 400 mg once daily from Day 1 of Cycle 1. It should be taken within 30 minutes after breakfast and continued throughout the neoadjuvant treatment period.

  • DrugTrastuzumab (H, 8mg/kg

    Drug page: TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trastuzumab will be administered intravenously at a loading dose of 8 mg/kg on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each subsequent 3-week cycle during neoadjuvant treatment.

  • DrugLiposomal doxorubicinStudies of Liposomal doxorubicinLiposomal doxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pegylated liposomal doxorubicin hydrochloride will be administered intravenously at 35 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment.

  • Cyclophosphamide will be administered intravenously at 600 mg/m² on Day 1 of each 3-week cycle for the first 4 cycles of neoadjuvant treatment in combination with pegylated liposomal doxorubicin hydrochloride, pyrotinib, and trastuzumab.

  • DrugPaclitaxel for Injection Albumin Bound

    Paclitaxel for injection albumin bound will be administered intravenously at 230-260 mg/m² on Day 1 of each 3-week cycle for the subsequent 4 cycles of neoadjuvant treatment in combination with pyrotinib and trastuzumab.

06

What researchers measure

Primary outcomes

  1. Total Pathological Complete Response Rate

    Total pathological complete response is defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes after neoadjuvant therapy.

    Time frame: At the time of surgery after completion of neoadjuvant therapy, approximately 24 weeks after treatment initiation

Secondary outcomes

  1. Secondary Outcome Measure

    Breast pathological complete response is defined as the absence of residual invasive cancer in the breast after neoadjuvant therapy.

    Time frame: At the time of surgery after completion of neoadjuvant therapy, approximately 24 weeks after treatment initiation

  2. Lymph Node Pathological Complete Response Rate

    Lymph node pathological complete response is defined as the absence of residual invasive cancer in axillary lymph nodes after neoadjuvant therapy.

    Time frame: At the time of surgery after completion of neoadjuvant therapy, approximately 24 weeks after treatment initiation

  3. Objective Response Rate

    Objective response rate is defined as the proportion of participants who achieve complete response or partial response according to RECIST version 1.1 during neoadjuvant therapy.

    Time frame: From baseline to completion of neoadjuvant therapy, approximately 24 weeks

  4. Event-Free Survival

    Event-free survival is defined as the time from enrollment to disease progression, recurrence, distant metastasis, second primary malignancy, or death from any cause, whichever occurs first.

    Time frame: From enrollment to the first documented event or death, assessed up to 3 years

  5. Distant Disease-Free Survival

    Distant disease-free survival is defined as the time from enrollment to the first occurrence of distant metastasis or death from any cause, whichever occurs first.

    Time frame: From enrollment to distant metastasis or death, assessed up to 3 years

  6. Overall Survival

    Overall survival is defined as the time from enrollment to death from any cause. Participants who are alive will be censored at the date of last follow-up.

    Time frame: From enrollment to death from any cause, assessed up to 3 years

  7. Number of Participants With Adverse Events

    Safety will be assessed by the incidence and severity of adverse events, graded according to NCI CTCAE version 5.0.

    Time frame: From the first dose of study treatment to 30 days after the last dose of neoadjuvant treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Xuhong J, Qi X, Tang P, Fan L, Chen L, Zhang F, Tan X, Yan W, Zhong L, He C, Liang Y, Ren L, Wang M, Zhang Y, Jiang J. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial. Oncologist. 2020 Dec;25(12):e1909-e1920. doi: 10.1002/onco.13546. Epub 2020 Oct 20. PubMed 33000490 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to participant privacy protection, ethical considerations, and the absence of a pre-specified individual participant data sharing plan in the current study protocol.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 32 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 9, 2026
StartActual
Apr 30, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2029
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07635342
Lead sponsor
Hebei Medical University Fourth Hospital
Responsible party
Zhenchuan Song (Chief Physician, Breast Center, Hebei Medical University Fourth Hospital) — Principal investigator
First posted
Jun 9, 2026
Start date
Apr 30, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 9, 2026

Study contacts

Zhenchuan Song, MD
Contact
songzhch@hotmail.com
18531117857
Lina Zhang, MD
Contact
+86 185 3111 7825
Zhenchuan Song
principal investigator · Hebei Medical University Fourth Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Shr-1258 dimaleate · Trastuzumab

Start the discussion